Sportradar Shareholders Elect Breon Corcoran, CEO of IG Group, to Board of Directors

(NASDAQ:SRAD),(NYSE:FLUT), ST. GALLEN, Switzerland, Dec. 15, 2025 (GLOBE NEWSWIRE) — Sportradar Group AG (NASDAQ: SRAD), a leading global sports technology company focused on creating immersive experiences for sports fans and bettors, today announced the election of Breon Corcoran, Chief Executive Officer of IG Group (LSEG:IGG), to its Board of Directors, effective December 11, 2025. Mr. […]

Quipt Home Medical Enters Into Definitive Agreement for Its Acquisition by Affiliates of Kingswood Capital Management and Forager Capital Management

(TSX:QIPT),(NASDAQ:QIPT), Quipt shareholders to receive US$3.65 per share in cash Transaction provides immediate liquidity and certainty of value to shareholders The per share purchase price represents a 162% premium to Quipt's unaffected stock price on May 19, 2025, the last full trading day prior to the public disclosure of Forager's $3.10 per share proposal, and

Bitcoin Bancorp Plans Deployment of Up to 200 Licensed Bitcoin ATMs Across Texas Beginning Q1 2026

(OtherOTC:BCBC),(OTC US:BCBC), LAS VEGAS, Dec. 15, 2025 (GLOBE NEWSWIRE) — Bitcoin Bancorp. (OTC: BCBC) (“Bitcoin Bancorp” or the “Company”), the only U.S. company holding foundational patents for Bitcoin ATMs and one of only three publicly traded Bitcoin ATM network owner/operators, today announced that it intends to deploy up to 200 licensed Bitcoin ATMs across the

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

(NASDAQ:TLSA), BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the withdrawal of the proposed public offering of common shares due to market conditions. This

Green Rain Energy Holdings Inc. (OTCID: GREH) Extends Holiday Greetings to Shareholders

(OtherOTC:GREH),(OTC US:GREH), BEVERLY HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) — Green Rain Energy Holdings Inc. (OTCID: GREH) (“Green Rain” or the “Company”) today announced that its management team and board of directors extend their sincere holiday wishes to all shareholders, partners, and stakeholders. As the year comes to a close, Green Rain Energy Holdings

3D Systems Announces FDA 510(k) Clearance Expanding VSP Orthopedics Indications to Include Skeletally Mature Adolescents

(NYSE:DDD), ROCK HILL, S.C., Dec. 15, 2025 (GLOBE NEWSWIRE) — 3D Systems (NYSE: DDD) today announced that the U.S. Food and Drug Administration has granted 510(k) clearance expanding the indications for its VSP(R) Orthopedics virtual surgical planning and patient-specific instrumentation platform to include skeletally mature adolescents of normal bone stature, in addition to adults. Key

Almadex Commences Diamond Drilling at The New Hope Copper Porphyry Project, Arizona, USA and Grants Stock Options

(TSX-V:DEX), VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) — Almadex Minerals Ltd. (“Almadex” or the “Company”) (TSX-V: “DEX”) is pleased to announce that it has started a scout exploration drill program at the Company's wholly owned New Hope copper-gold porphyry prospect in Arizona. The initial hole of the program is not expected to be

Abeona Therapeutics(R) Announces Appointment of Mohamad Tabrizi as Chief Business Officer

(NASDAQ:ABEO), CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company's corporate strategy and business development functions, as well as drive operating efficiency for the Company. “Mohamad

Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025

(NasdaqGM:PFSA), Data from FDA-advised study demonstrates Lumee(TM) Oxygen tissue monitoring is a safe and effective long-term method in PAD patients and will support potential FDA submission; strongly correlates with transcutaneous partial pressure of oxygen BERKELEY, Calif, Dec. 15, 2025 (GLOBE NEWSWIRE) — Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

(NASDAQ:MDCX), THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026 PHILADELPHIA, Dec. 15, 2025 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company

Scroll to Top